Lilly’s Revenue Boost Masks Earnings Caution | Business and Finance News

Eli Lilly’s Q2 earnings missed revenue targets but dazzled investors with strong cash flow from heart health, cancer, and neuroscience drugs—fueling optimism as they push new therapies and expand globally. Yet the company dialed back full-year EPS guidance due to one-time adjustments and seasonal diabetes headwinds, while pouring resources into manufacturing and R&D. Analysts zeroed in on the timeline for their obesity drug retatrutide, now expected for FDA review in early 2027, and Lilly’s strategy to broaden access for these high-demand treatments. The stock’s rebound hints at momentum—but the real test lies in regulatory approvals and market penetration. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2a95ccbe932da856